AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Sep 11, 2021

To treat or not: guidance for managing complicated urinary tract infections

Panelists will discuss how to manage complicated urinary tract infections in the absence of specific guidelines


From left: A. Lenore Ackerman, MD, MPH; Christina B. Ching, MD; Manoj Monga, MD, FACS, FRCS; and Daniel Arthur Shoskes, MD
From left: A. Lenore Ackerman, MD, MPH; Christina B. Ching, MD; Manoj Monga, MD, FACS, FRCS; and Daniel Arthur Shoskes, MD

It’s estimated that 10% to 20% of urinary tract infection (UTI) cases are complicated.

“A common scenario: You’re on call in the hospital and get notified about a patient with pyelonephritis,” said A. Lenore Ackerman, MD, MPH. “The hospital physician relays that a CT scan revealed a small stone. ‘It’s not blocking anything,’ the physician says. ‘But you need to take care of it because the patient has pyelonephritis.’” What to do? The new 2019 UTI guidelines provide an evidence-based approach for diagnosing and managing uncomplicated recurrent UTIs in women. Still, managing complex cases, such as patients with asymptomatic stones or those with neurogenic bladders dependent on a Foley catheter, can present a conundrum. “For complicated cases, there’s no real guidance that says we should or shouldn’t treat,” Dr. Ackerman said.

Sunday’s session, “Panel Discussion: The Challenging Patient with Recurrent UTI,” will provide advice for clinically managing these and other complex types of UTI cases the new guidelines don’t specifically address.

“We will be discussing some of those more complicated situations and the available evidence, what is still unknown, and get advice from experts on how to approach some of these challenging situations,” said Dr. Ackerman, the session’s moderator. Dr. Ackerman is assistant professor of urology at the David Geffen School of Medicine at UCLA Health and director of research in pelvic medicine and reconstructive surgery at the UCLA Center for Women’s Pelvic Health.

Dr. Ackerman will lead a panel discussion with Christina B. Ching, MD, a member of the section of pediatric urology at Nationwide Children's Hospital in Columbus, Ohio; Daniel Arthur Shoskes, MD, a urologist with the Cleveland Clinic in Cleveland, Ohio; and Manoj Monga, MD, FACS, FRCS, professor and chair of the department of urology at the University of California San Diego School of Medicine.

The panelists will discuss how to use an evidence-based approach for managing complicated but common clinical scenarios in which complex urologic diagnoses intersect with unclear definitions of infection, given the absence of specific evidence-based guidelines and our emerging understanding of the microbiome and the urinary tract.  

“In the past couple of years, we’ve come to understand that bacteriuria can sometimes be protective,” Dr. Ackerman said. “Our evolving understanding is that bacteria are with us all the time, and they’re an integral part of the urinary tract in healthy people. This new understanding has made managing challenging UTI cases even harder because what constitutes an infection is more unclear than it has ever been.” When does bacteriuria signal an infection, and when may it be beneficial? What is the best way to treat bacteriuria? When is it best not to treat? “Those questions are as pertinent for complicated UTIs as uncomplicated UTIs,” Dr. Ackerman said.

“In Sunday’s session, we’ll to try to face these and other questions and discuss what we know and what still needs to be better explored for managing complicated UTI,” she said. 

Visit AUA2021 Daily News Online for more articles.

Interesting Stories
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
More Content
Getty Images 1208851295
AUA2022
Save the date
Jan 31, 2022
Aua Wrap 04
AUA2021
AUA2021 On Demand: see what’s streaming
Sep 22, 2021
Aua Wrap 03
AUA2021
Satellite symposia bring expert insights
Sep 22, 2021
Aua Wrap 01
AUA2021
Education and training for young urologists
Sep 22, 2021
Getty Images 1199215126
AUA2021
Claim your CME
Sep 22, 2021
Aua Wrap 05
AUA2021
Read all about it
Sep 22, 2021
Aua Tv
AUA2021
Must-see TV
Sep 22, 2021
Getty Images 185224486
AUA2021
AUA2021: By the numbers
Sep 15, 2021
Toni K. Choueiri, MD
AUA2021
Late-breaking science
Sep 15, 2021
Ian M. Thompson Jr., MD
AUA2021
Award winners
Sep 15, 2021
Tips And Tricks
AUA2021
Guideline updates
Sep 15, 2021
Ai
AUA2021
New technology
Sep 15, 2021
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.